Cytochrome P450 3A4 genetic polymorphisms and post-operative fentanyl requirements

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 100-104

  Tan, P C S ^a   Hassan, S K ^a   Mohamad, N A N ^a   Gan, S H ^b  

^a Department of Anaesthesiology and Intensive Care ^*  (Malaysia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

CYP3A4 polymorphism; fentanyl; patient controlled analgesia; pharmacogenomics

Indexed keywords

CYTOCHROME P450 3A4; FENTANYL;

ADULT; ALLELE; ANALGESIA; ANESTHESIA INDUCTION; ARTICLE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENERAL ANESTHESIA; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; NAUSEA; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRURITUS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VISUAL ANALOG SCALE; VOMITING;

ADULT; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP3A; FEMALE; FENTANYL; GENOTYPE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; INFUSIONS, INTRAVENOUS; LAPAROTOMY; MALAYSIA; MIDDLE AGED; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 84856320021     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01232.x     Document Type: Article

References (23)

1. Evans WE, Relling MV.,. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999; 286: 487-491.
2. Rendic S, Carlo FJ,. Human cytochrome P450 enzyme: a status report summarizing their reaction, substrates, inducers and inhibitors. Drug Metabolism Reviews, 1997; 29: 413-580. (Pubitemid 27293618)
3. Thummel KE, Wilkinson GR,. In vitro and in vivo drug interactions involving human CYP3A4. Annual Review of Pharmacology and Toxicology, 1998; 38: 389-430. (Pubitemid 28231501)
4. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA,. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. The Journal of Pharmacology and Experimental Therapeutics, 2001; 299: 825-831. (Pubitemid 33104948)
5. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD,. Novel mutations of CYP3A4 in Chinese. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 2001; 29: 268-273.
6. Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C.,. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clinica Chimica Acta; International Journal of Clinical Chemistry, 2005; 353: 187-192. (Pubitemid 40215445)
7. Liu CH, Peck K, Huang JD, et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics, 2005; 6: 731-747. (Pubitemid 41479418)
8. Ruzilawati AB, Suhaimi AW, Gan SH,. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clinica Chimica Acta; International Journal of Clinical Chemistry, 2007; 383: 158-162. (Pubitemid 47016453)
9. Kang YS, Park SY, Yim CH, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clinical Pharmacology and Therapeutics, 2009; 85: 312-318.
10. Lee SJ, Lee SS, Jeong HE, et al. The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 2007; 35: 2095-2101.
11. Ruzilawati AB, Suhaimi AW, Gan SH,. Effect of CYP3A4*18 on repaglinide's pharmacokinetics. Drug Metabolism Reviews, 2008; 40 (S1), 139.
12. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M,. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesthesia and Analgesia, 1996; 82: 167-172. (Pubitemid 26017401)
13. Feierman DE, Lasker JM,. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 1996; 24: 932-939. (Pubitemid 26314543)
14. Guitton J, Buronfosse T, Desage M, Lepape A, Brazier JL, Beaune P,. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochemical Pharmacology, 1997; 53: 1613-1619. (Pubitemid 27356090)
15. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM,. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clinical Chemistry, 2000; 46: 18-23. (Pubitemid 30090955)
16. Edwards AW,. G. H. Hardy (1908) and Hardy-Weinberg equilibrium. Genetics, 1908; 179: 1143-1150.
17. Jamison RN, (1993) Clinical measurement of pain. In:, Ferrante FM, VadeBonCouer TR, eds. Clinical measurement of pain, 1st edn. New York: Churchill Livingstone, 119-132.
18. Pandit JJ,. 'Hardy's law' and genomics in anaesthesia. Anaesthesia, 2008; 63: 1284-1287.
19. Jung H, Lee S, Jung H, Shon J, Cha I, Shin J,. Allelic distribution of CYP3A4 genetic polymorphism in Korean population. Clinical Pharmacology and Therapeutics, 2002; 73: P41.
20. Yamamoto T, Nagafuchi N, Ozeki T, et al. CYP3A4*18: it is not rare allele in Japanese population. Drug Metabolism and Pharmacokinetics, 2003; 18: 267-268.
21. Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica, 2007; 37: 315-327.
22. Kissin I,. Patient-controlled-analgesia analgesimetry and its problems. Anesthesia and Analgesia, 2009; 108: 1945-1949.
23. Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH,. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. Journal of Analytical Toxicology, 2005; 29: 590-598. (Pubitemid 41803344)